In the Consortium on Resistance Against Carbapenems in and other (CRACKLE), trimethoprim-sulfamethoxazole (TMP-SMX) had a limited role in the treatment of less severe carbapenem-resistant (CRE) infections, especially urinary tract infections. Of tested CRE, only 29% were susceptible to TMP-SMX. Development of resistance further limits the use of TMP-SMX in CRE infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324543 | PMC |
| http://dx.doi.org/10.1093/ofid/ofy351 | DOI Listing |
Publication Analysis
Top Keywords
cre infections
8
role trimethoprim/sulfamethoxazole
4
trimethoprim/sulfamethoxazole treatment
4
infections
4
treatment infections
4
infections caused
4
caused carbapenem-resistant
4
carbapenem-resistant consortium
4
consortium resistance
4
resistance carbapenems
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!